FR2789079B3
(fr)
*
|
1999-02-01 |
2001-03-02 |
Sanofi Synthelabo |
Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
|
FR2799124B1
(fr)
*
|
1999-10-01 |
2004-08-13 |
Sanofi Synthelabo |
Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
|
US7393842B2
(en)
*
|
2001-08-31 |
2008-07-01 |
University Of Connecticut |
Pyrazole analogs acting on cannabinoid receptors
|
FR2804604B1
(fr)
*
|
2000-02-09 |
2005-05-27 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
|
FR2809621B1
(fr)
*
|
2000-05-12 |
2002-09-06 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
BR0211705A
(pt)
*
|
2001-08-06 |
2004-09-28 |
Astrazeneca Ab |
Processo para a preparação de uma dispersão estável de partìculas sólidas em um meio aquoso, dispersão estável aquosa, partìcula sólida, composição farmacêutica, método para a inibição do amadurecimento de ostwald em uma dispersão de partìculas sólidas substancialmente insolúveis em água em um meio aquoso, e, uso de um inibidor
|
US7109216B2
(en)
*
|
2001-09-21 |
2006-09-19 |
Solvay Pharmaceuticals B.V. |
1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
|
RU2299199C2
(ru)
|
2001-09-21 |
2007-05-20 |
Солвей Фармасьютикалс Б.В. |
Новые производные 4,5-дигидро-1h-пиразола, имеющие cb1-антагонистическую активность
|
TWI231757B
(en)
*
|
2001-09-21 |
2005-05-01 |
Solvay Pharm Bv |
1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
|
CN1529595A
(zh)
|
2001-09-21 |
2004-09-15 |
������ҩ������˾ |
具有效cb1-拮抗活性的4,5-2氢-1h-吡唑衍生物
|
WO2003075917A1
(en)
|
2002-03-08 |
2003-09-18 |
Signal Pharmaceuticals, Inc. |
Combination therapy for treating, preventing or managing proliferative disorders and cancers
|
AR038966A1
(es)
|
2002-03-18 |
2005-02-02 |
Solvay Pharm Bv |
Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
|
FR2837706A1
(fr)
*
|
2002-03-28 |
2003-10-03 |
Sanofi Synthelabo |
Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
|
AU2003225964B2
(en)
*
|
2002-03-28 |
2008-11-20 |
Merck Sharp & Dohme Corp. |
Substituted 2,3-diphenyl pyridines
|
US6825209B2
(en)
|
2002-04-15 |
2004-11-30 |
Research Triangle Institute |
Compounds having unique CB1 receptor binding selectivity and methods for their production and use
|
US6972291B2
(en)
*
|
2002-07-02 |
2005-12-06 |
Bernstein Richard K |
Method for reducing food intake
|
GB0216700D0
(en)
*
|
2002-07-18 |
2002-08-28 |
Astrazeneca Ab |
Process
|
KR100741231B1
(ko)
|
2002-07-29 |
2007-07-19 |
에프. 호프만-라 로슈 아게 |
신규 벤조다이옥솔
|
US7319110B2
(en)
*
|
2002-09-19 |
2008-01-15 |
Solvay Pharmaceuticals B.V. |
1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity
|
SE0203070D0
(en)
|
2002-10-16 |
2002-10-16 |
Astrazeneca Ab |
Novel compounds
|
EP1556373A1
(en)
*
|
2002-10-18 |
2005-07-27 |
Pfizer Products Inc. |
Cannabinoid receptor ligands and uses thereof
|
US7129239B2
(en)
*
|
2002-10-28 |
2006-10-31 |
Pfizer Inc. |
Purine compounds and uses thereof
|
US7247628B2
(en)
*
|
2002-12-12 |
2007-07-24 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
FR2849032B1
(fr)
*
|
2002-12-23 |
2006-04-28 |
Sanofi Synthelabo |
Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique
|
GB0230087D0
(en)
*
|
2002-12-24 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
GB0230088D0
(en)
*
|
2002-12-24 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
WO2004060870A1
(en)
*
|
2003-01-02 |
2004-07-22 |
F. Hoffmann-La Roche Ag |
Novel cb 1 receptour inverse agonists
|
ATE400571T1
(de)
|
2003-01-02 |
2008-07-15 |
Hoffmann La Roche |
Pyrrolyl-thiazole und ihre verwendung als inverse agonisten des cb 1 rezeptors
|
GB0302672D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
US7329658B2
(en)
*
|
2003-02-06 |
2008-02-12 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
GB0302673D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
GB0302671D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
US7176210B2
(en)
*
|
2003-02-10 |
2007-02-13 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
US20060172019A1
(en)
*
|
2003-03-07 |
2006-08-03 |
Ralston Stuart H |
Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
|
US7141669B2
(en)
*
|
2003-04-23 |
2006-11-28 |
Pfizer Inc. |
Cannabiniod receptor ligands and uses thereof
|
US7268133B2
(en)
*
|
2003-04-23 |
2007-09-11 |
Pfizer, Inc. Patent Department |
Cannabinoid receptor ligands and uses thereof
|
US7145012B2
(en)
|
2003-04-23 |
2006-12-05 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
US20040214856A1
(en)
*
|
2003-04-23 |
2004-10-28 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
JP4041153B2
(ja)
*
|
2003-05-07 |
2008-01-30 |
ファイザー・プロダクツ・インク |
カンナビノイド受容体リガンドとその使用
|
US7232823B2
(en)
|
2003-06-09 |
2007-06-19 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
SE0301698D0
(sv)
*
|
2003-06-10 |
2003-06-10 |
Astrazeneca Ab |
Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
|
SE0301701D0
(sv)
*
|
2003-06-10 |
2003-06-10 |
Astrazeneca Ab |
Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
|
SE0301699D0
(sv)
*
|
2003-06-10 |
2003-06-10 |
Astrazeneca Ab |
Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
|
US20040259887A1
(en)
*
|
2003-06-18 |
2004-12-23 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
EP1641779A1
(en)
*
|
2003-06-18 |
2006-04-05 |
AstraZeneca AB |
2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
|
GB0314057D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
GB0314261D0
(en)
*
|
2003-06-19 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
CA2528785A1
(en)
|
2003-06-20 |
2005-01-06 |
Matthias Heinrich Nettekoven |
2-amidobenzothiazoles as cb1 receptor inverse agonists
|
US7517900B2
(en)
|
2003-10-10 |
2009-04-14 |
Bristol-Myers Squibb Company |
Pyrazole derivatives as cannabinoid receptor modulators
|
FR2861303A1
(fr)
*
|
2003-10-24 |
2005-04-29 |
Sanofi Synthelabo |
Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
|
FR2861301B1
(fr)
*
|
2003-10-24 |
2008-07-11 |
Sanofi Synthelabo |
Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
|
FR2861300B1
(fr)
*
|
2003-10-24 |
2008-07-11 |
Sanofi Synthelabo |
Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
|
FR2861302A1
(fr)
*
|
2003-10-24 |
2005-04-29 |
Sanofi Synthelabo |
Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
|
AU2004299198A1
(en)
|
2003-12-08 |
2005-06-30 |
F. Hoffmann-La Roche Ag |
Novel thiazole derivates
|
CA2553970A1
(en)
|
2004-01-28 |
2005-08-18 |
F. Hoffmann-La Roche Ag |
Spiro-benzodioxoles and their use as cb1 antagonists
|
US7649002B2
(en)
|
2004-02-04 |
2010-01-19 |
Pfizer Inc |
(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
|
FR2866340B1
(fr)
*
|
2004-02-13 |
2006-11-24 |
Sanofi Synthelabo |
Derives d'oxazole, leur preparation et leur utilisation en therapeutique.
|
US20090149463A1
(en)
*
|
2004-02-20 |
2009-06-11 |
Leifeng Cheng |
Therapeutic agents
|
EP1574211A1
(en)
|
2004-03-09 |
2005-09-14 |
Inserm |
Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
|
US7262318B2
(en)
*
|
2004-03-10 |
2007-08-28 |
Pfizer, Inc. |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
FR2867685B1
(fr)
*
|
2004-03-17 |
2008-05-23 |
Sanofi Synthelabo |
Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement de la bronchite chronique et de la broncho-pneumopathie chronique obstructive
|
BRPI0510679A
(pt)
|
2004-05-10 |
2007-12-26 |
Hoffmann La Roche |
compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização desses compostos
|
ITMI20041032A1
(it)
*
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Compositi farmaceutici
|
US20050288340A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Pfizer Inc |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
WO2006025069A2
(en)
|
2004-07-12 |
2006-03-09 |
Cadila Healthcare Limited |
Tricyclic pyrazole derivatives as cannabinoid receptor modulators
|
US20060025448A1
(en)
|
2004-07-22 |
2006-02-02 |
Cadila Healthcare Limited |
Hair growth stimulators
|
EP1807070A1
(en)
*
|
2004-09-29 |
2007-07-18 |
Schering Corporation |
Combinations of substituted azetidinones and cb1 antagonists
|
ATE399156T1
(de)
|
2004-10-27 |
2008-07-15 |
Hoffmann La Roche |
Neue indol- oder benzimidazol-derivate
|
AU2005304039A1
(en)
|
2004-11-09 |
2006-05-18 |
F. Hoffmann-La Roche Ag |
Dibenzosuberone derivatives
|
CA2589483C
(en)
|
2004-12-03 |
2013-10-29 |
Schering Corporation |
Substituted piperazines as cb1 antagonists
|
WO2006067443A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Astrazeneca Ab |
Therapeutic agents
|
FR2880023B1
(fr)
|
2004-12-23 |
2007-02-23 |
Sanofi Aventis Sa |
Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
|
CA2594488C
(en)
*
|
2005-01-10 |
2015-04-28 |
University Of Connecticut |
Novel heteropyrrole analogs acting on cannabinoid receptors
|
US8853205B2
(en)
|
2005-01-10 |
2014-10-07 |
University Of Connecticut |
Heteropyrrole analogs acting on cannabinoid receptors
|
PA8660701A1
(es)
|
2005-02-04 |
2006-09-22 |
Pfizer Prod Inc |
Agonistas de pyy y sus usos
|
FR2881744B1
(fr)
|
2005-02-09 |
2007-04-27 |
Sanofi Aventis Sa |
Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
|
FR2882261B1
(fr)
*
|
2005-02-21 |
2009-02-06 |
Sanofi Aventis Sa |
Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
|
FR2882264A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Sanofi Aventis Sa |
Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
|
UY29386A1
(es)
*
|
2005-02-21 |
2006-10-02 |
Sanofi Aventis |
Utilizción de rimonabant para la preparación de medicamentos útiles en la prevención y el tratamiento de la diabetes de tipo2.
|
FR2882262B1
(fr)
*
|
2005-02-23 |
2007-04-06 |
Sanofi Aventis Sa |
Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
|
FR2882263B1
(fr)
*
|
2005-02-23 |
2007-04-06 |
Sanofi Aventis Sa |
Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
|
FR2882931B1
(fr)
*
|
2005-03-14 |
2007-05-18 |
Sanofi Aventis Sa |
Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique
|
DK1868999T3
(da)
|
2005-04-06 |
2009-08-17 |
Hoffmann La Roche |
Pyridin-3-carboxamidderivater som omvendte CB1-agonister
|
WO2006129193A2
(en)
*
|
2005-05-27 |
2006-12-07 |
Pfizer Products Inc. |
Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
|
GB0514738D0
(en)
*
|
2005-07-19 |
2005-08-24 |
Astrazeneca Ab |
Therapeutic agents
|
GB0514739D0
(en)
*
|
2005-07-19 |
2005-08-24 |
Astrazeneca Ab |
Therapeutic agents
|
CA2617654A1
(en)
*
|
2005-08-04 |
2007-02-08 |
Pfizer Limited |
Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
|
CA2518579A1
(en)
*
|
2005-08-05 |
2007-02-05 |
University Technologies International Inc. |
Method for appetite suppression
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
CN100999517B
(zh)
*
|
2006-01-11 |
2010-12-15 |
北京摩力克科技有限公司 |
吡唑甲酰胺衍生物,药物组合物和其制备方法
|
CA2637565A1
(en)
|
2006-01-18 |
2007-07-26 |
Schering Corporation |
Cannibinoid receptor modulators
|
EA200801738A1
(ru)
*
|
2006-02-23 |
2008-12-30 |
Пфайзер Лимитед |
Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа
|
AU2007226673A1
(en)
*
|
2006-03-10 |
2007-09-20 |
Jenrin Discovery |
Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
|
RU2424242C2
(ru)
|
2006-03-30 |
2011-07-20 |
Айрм Ллк |
Азолопиримидины в качестве ингибиторов активности каннабиноидного рецептора 1
|
WO2007121687A1
(fr)
*
|
2006-04-26 |
2007-11-01 |
Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China |
Dérivés du 4-méthyl-1h-diaryl pyrazole et leur utilisation comme médicaments
|
CN101062919B
(zh)
*
|
2006-04-26 |
2012-08-15 |
中国人民解放军军事医学科学院毒物药物研究所 |
4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
|
FR2902008A1
(fr)
*
|
2006-06-07 |
2007-12-14 |
Sanofi Aventis Sa |
Utilisation d'un antagoniste des recepteurs cb1 aux cannabinoides pour la preparation de medicaments utiles pour la prevention et le traitement de l'hypertrophie begnine de la prostate
|
US7629346B2
(en)
|
2006-06-19 |
2009-12-08 |
Hoffmann-La Roche Inc. |
Pyrazinecarboxamide derivatives as CB1 antagonists
|
BRPI0716134A2
(pt)
|
2006-09-07 |
2013-09-17 |
Nycomed Gmbh |
tratamento de combinaÇço para diabetes mellitus
|
EP2061783A2
(en)
*
|
2006-09-11 |
2009-05-27 |
Hetero Drugs Limited |
Improved process for rimonabant
|
US7781593B2
(en)
*
|
2006-09-14 |
2010-08-24 |
Hoffmann-La Roche Inc. |
5-phenyl-nicotinamide derivatives
|
US7875647B2
(en)
|
2006-09-29 |
2011-01-25 |
Green Cross Corporation |
Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
|
KR20090064478A
(ko)
|
2006-11-13 |
2009-06-18 |
화이자 프로덕츠 인크. |
디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도
|
FR2909090B1
(fr)
|
2006-11-23 |
2009-01-09 |
Sanofi Aventis Sa |
Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique.
|
CN101663262B
(zh)
|
2006-12-01 |
2014-03-26 |
百时美施贵宝公司 |
用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
|
JP5437812B2
(ja)
|
2006-12-18 |
2014-03-12 |
7ティーエム ファーマ エイ/エス |
Cb1受容体モジュレーター
|
FR2911136B1
(fr)
|
2007-01-05 |
2009-02-20 |
Sanofi Aventis Sa |
Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
|
GB0702862D0
(en)
*
|
2007-02-14 |
2007-03-28 |
Univ Aberdeen |
Therapeutic compounds
|
WO2008102367A1
(en)
*
|
2007-02-19 |
2008-08-28 |
Darmesh Mahendrabhai Shah |
Process for preparation of pyrazole derivatives
|
FR2913018A1
(fr)
*
|
2007-02-23 |
2008-08-29 |
Sanofi Aventis Sa |
Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs
|
US20100197564A1
(en)
*
|
2007-04-19 |
2010-08-05 |
Schering Corporation |
Diaryl morpholines as cb1 modulators
|
MX2009013354A
(es)
|
2007-06-04 |
2010-07-06 |
Univ Ben Gurion |
Compuestos de triarilo y composiciones que los contienen.
|
WO2009005671A2
(en)
*
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Substituted piperazines as cb1 antagonists
|
RU2010102478A
(ru)
*
|
2007-06-28 |
2011-08-10 |
Интэрвэт Интэрнэшнл Б.Ф. (NL) |
Замещенные пиперазины как антагонисты св1
|
FR2919861A1
(fr)
*
|
2007-08-06 |
2009-02-13 |
Sanofi Aventis Sa |
Le solvate d'isopranol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
|
US8133904B2
(en)
*
|
2007-09-07 |
2012-03-13 |
Jenrin Discovery, Inc. |
Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
|
WO2010013240A1
(en)
|
2008-07-31 |
2010-02-04 |
Dekel Pharmaceuticals Ltd. |
Compositions and methods for treating inflammatory disorders
|
AU2009278838B2
(en)
*
|
2008-08-06 |
2013-07-25 |
Pfizer Limited |
Diazepine and diazocane compounds as MC4 agonists
|
WO2010079241A1
(es)
|
2009-01-12 |
2010-07-15 |
Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion |
Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
|
US10053444B2
(en)
|
2009-02-19 |
2018-08-21 |
University Of Connecticut |
Cannabinergic nitrate esters and related analogs
|
US8410107B2
(en)
|
2010-10-15 |
2013-04-02 |
Hoffmann-La Roche Inc. |
N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
|
US8669254B2
(en)
|
2010-12-15 |
2014-03-11 |
Hoffman-La Roche Inc. |
Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
|
WO2013068371A1
(en)
|
2011-11-08 |
2013-05-16 |
Intervet International B.V. |
Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
|
AU2014347668A1
(en)
|
2013-11-05 |
2016-05-19 |
Ben-Gurion University Of The Negev Research And Development Authority |
Compounds for the treatment of diabetes and disease complications arising from same
|
CA3125847A1
(en)
|
2020-07-27 |
2022-01-27 |
Makscientific, Llc |
Process for making biologically active compounds and intermediates thereof
|